TB-500 (Thymosin Beta-4 Fragment)
An investigational thymosin beta-4 fragment researched for cellular migration and tissue-repair pathways; human exposure and safety data are limited.
OVERVIEW
TB-500 is a synthetic fragment associated with thymosin beta-4, a naturally occurring protein involved in cellular migration and repair processes. The marketed TB-500 fragment is not an FDA-approved drug.
Proposed Mechanisms
• Proposed actin regulation • Cellular migration • Angiogenesis • Tissue remodeling • Anti-inflammatory signaling
Potential Applications
• Investigational sports-injury research • Tendon and soft-tissue recovery research • Joint-support research
Pharmacokinetics
Human pharmacokinetics are not established. The source draft estimated a 2–7 day half-life and systemic distribution; these estimates should not be treated as validated clinical parameters.
Dosing
No FDA-approved human dosing. The source draft listed 2–5 mg weekly for 4–8 weeks, followed by 2–5 mg monthly; these are investigational protocol references, not recommendations.
Monitoring
No standardized monitoring protocol. The source draft suggested functional recovery and pain assessment.
Side Effects
Human safety data are limited. The source draft noted fatigue and injection-site discomfort.
Contraindications
No FDA-approved labeling or established contraindication profile; clinician review is required.
FDA/Investigational Status
Not FDA-approved. FDA states that it has not identified human-exposure data for the TB-500 fragment and lacks sufficient information to assess safety. FDA advisory review of bulk substances does not constitute approval.
Disclaimer/Notes
Educational resource only. Avoid wording that implies proven healing effects or routine clinical availability.
Clinical Review Status
Clinical + legal review required before publishing